Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Taro Pharmaceutical Industries

    Jump to

    • Taro appoints Sun Pharma CFO Uday Baldota its CEO

    • Sun Pharma's arm Taro plans shares repurchase worth USD 250mn

    • Taro Q4 net income spikes 70% to $152.3 mn

    • Sun Pharma's Taro Q3 net income jumps 28.7% to $142.5 m

    • Sun Pharma Q1 net profit seen up 30% to Rs 1,035cr

      Sun Pharma's revenue is expected to rise 23 percent year-on-year to Rs 3,287 crore, driven by over 20 percent growth in US sales. Domestic formulations sales are, however, likely to be lower due to the impact of the new drug pricing policy.

    • Sun Pharma declines after Taro's Q1 earnings drop

      Israel-based Taro's first quarter net income declined 7 percent, while revenue fell 4 percent, which the company said was due to a one-time charge taken to meet contractual obligations.

    • Sun Pharma gains on higher prices for drugs

      Shares in Sun Pharmaceutical Industries gain 1.8 percent after Credit Suisse said the drug maker's subsidiary Taro Pharmaceutical Industries has pushed through price increases in three products last week, citing industry checks.

    Advisory Alert:

    It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347